drug
STELARA
updated 3mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval270 co-mentions · 91 sources
- drugustekinumab223 co-mentions · 91 sources
- tagOrthopedics60 co-mentions · 30 sources
- companyJanssen Biotech Inc28 co-mentions · 14 sources
- drugPYZCHIVA26 co-mentions · 13 sources
- drugOTULFI18 co-mentions · 9 sources
- companySamsung Bioepis Co Ltd13 co-mentions · 13 sources
- drugWEZLANA12 co-mentions · 6 sources
all catalysts(0)
nothing on the calendar yet
Trials studying STELARA
- phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- phase3A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
- phase3A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- phase3Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- phase3A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- —A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- phase3A Long-term Extension Study of Ustekinumab in Pediatric Participants
News(5)
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 6h ago
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillSet to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.biopharma_dive · 28d ago
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 1mo ago
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BThe buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.biopharma_dive · 2mo ago
- AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsA handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.biopharma_dive · 2mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that